Genetic determinants of BMI, diet, and fitness interact to partially explain anthropometric obesity traits but not the metabolic consequences of obesity in men and women
February 20, 2026 / Polygenic Risk Score / Precision Nutrition / Metabolic Syndrome / Obesity Genetics / Body Composition Analysis
BMI polygenic risk scores significantly predicted BMI and select adiposity measures but showed limited association with metabolic syndrome traits. Sex, fitness, and resting metabolic rate were stronger determinants of metabolic dysfunction, highlighting distinct genetic drivers of obesity versus its metabolic consequences.
Triggering Self-Combustion in Fat Cells for Weight Loss
February 23, 2025 / White Adipocyte Thermogenesis / Mitochondrial Uncoupling / AAC Enzyme / Obesity Treatment Innovation / Metabolic Energy Expenditure
Preclinical research demonstrates that activating AAC-mediated mitochondrial uncoupling in white adipocytes induces thermogenesis and increases energy expenditure in obese mice, suggesting a targeted, potentially safer strategy for weight loss distinct from systemic uncoupling or appetite-suppressing pharmacotherapies.
New review explores whether berries can slow cognitive decline linked to obesity
February 22, 2026 / Berries and Cognitive Decline / Obesity and Alzheimer’s Risk / Polyphenols and Insulin Sensitivity / Gut-Brain Axis / Anthocyanins and Neuroprotection
A systematic review suggests polyphenol-rich berries may modestly improve memory and metabolic parameters in obesity by enhancing insulin sensitivity, reducing inflammation, and modulating gut-brain signaling, though human evidence for consistent amyloid and tau biomarker changes remains limited.
The GLP-1 revolution: What UAB researchers are discovering about how these drugs work
February 18, 2026 / GLP-1 Mechanism of Action / Tirzepatide Dual Agonist / Dopamine and Appetite Regulation / Neuroendocrine Obesity Treatment / GIP GLP-1 Synergy
UAB researchers highlight that GLP-1 receptor agonists suppress appetite through brain-mediated satiety and dopamine reward modulation, while multi-receptor agents like tirzepatide enhance metabolic and adipocyte effects, demonstrating synergistic neuroendocrine mechanisms beyond glucose control.
Why Cardiovascular, Kidney, Metabolic Risk Must Be Managed Together, With Janani Rangaswami, MD, FAHA
February 19, 2026 / Cardiovascular Kidney Metabolic Syndrome / CKM Staging Model / Semaglutide FLOW Trial / Type 2 Diabetes and CKD / Cardiorenal Risk Reduction
CKM staging integrates obesity, diabetes, hypertension, CKD, and cardiovascular disease as a continuum, supporting early combination therapy. Evidence from FLOW shows semaglutide reduces kidney progression, cardiovascular events, and mortality, reinforcing multi-organ, multi-risk treatment strategies in high-risk T2D populations.
New Study on Obesity Criteria Shows: Vast Majority of Affected Individuals are Classified as Clinically Obese
February 23, 2026 / Clinical vs Preclinical Obesity / BMI and Cardiometabolic Risk / Type 2 Diabetes Risk / Cardiovascular Disease and Obesity / Lifestyle Intervention Outcomes
Large cohort analyses show ~80% of individuals with BMI ≥30 kg/m² meet criteria for clinical obesity, with 3-fold higher cardiovascular and 8-fold higher type 2 diabetes risk. Lifestyle intervention significantly reduced cardiometabolic abnormalities, questioning the necessity of additional anthropometric confirmation.
Higher ultra-processed food intake aligns with greater binge eating risk in obesity study
February 23, 2026 / Ultra-Processed Foods and Obesity / Binge Eating Risk / NOVA Food Classification / Neuroendocrine Appetite Regulation / Diet Quality and Metabolic Health
In adults with obesity, higher ultra-processed food intake was associated with increased binge eating risk, suggesting UPFs may disrupt appetite-regulating neuroendocrine pathways and exacerbate disordered eating behaviors, potentially undermining obesity treatment effectiveness.
Zandra Healthcare launches Metabolic Health Centre with AI-based diagnostics
February 23, 2026 / AI-Based Metabolic Diagnostics / Predictive Care Model / Diabetic Foot Prevention Technology / GLP-1 Obesity Treatment Integration / Metabolic Syndrome Management
Zandra Healthcare’s Metabolic Health Centre integrates AI-based diagnostics, point-of-care cardiometabolic testing, gait analysis for diabetic foot prevention, sleep and pulmonary assessment, and body composition profiling, advancing predictive, multi-organ management of obesity, diabetes, and metabolic syndrome complications.
Modulation of metabolic, inflammatory, fibrotic, and cell death pathways by resmetirom in metabolic dysfunction-associated steatohepatitis (MASH): a transcriptomic profiling study
February 19, 2026 / Resmetirom in MASH / Metabolic Dysfunction-Associated Steatohepatitis / MASLD Treatment Advances / Liver Fibrosis Pathways / Metabolic Syndrome and Liver Disease
Transcriptomic profiling shows resmetirom modulates metabolic, inflammatory, fibrotic, and cell death pathways in metabolic dysfunction–associated steatohepatitis (MASH), supporting its therapeutic role in targeting underlying liver injury mechanisms linked to obesity, insulin resistance, and metabolic syndrome.
The future of MASH treatment: Multi-mechanistic approaches
February 17, 2026 / Pemvidutide Dual Agonist / MASH Treatment Pipeline / Glucagon GLP-1 Therapy / Liver Fibrosis Improvement / Metabolic Liver Disease Innovation
Pemvidutide, a balanced glucagon/GLP-1 dual agonist, demonstrated MASH resolution, antifibrotic activity, and weight loss in Phase 2b trials, supporting multi-mechanistic targeting of metabolic and hepatic pathways. Phase 3 development aims to deliver durable, tolerable treatment for progressive liver disease.
Adipose tissue–derived MFG-E8 promotes hepatic inflammation and fibrosis through macrophage activation in a mouse MASH model
February 20, 2026 / MFG-E8 and MASH / Adipose Liver Crosstalk / Hepatic Inflammation Mechanisms / Macrophage Activation in Fibrosis / Metabolic Liver Disease Pathways
In a mouse MASH model, adipose-derived MFG-E8 promoted hepatic inflammation and fibrosis via macrophage activation and enhanced macrophage–hepatocyte interactions, independent of steatosis, identifying a novel adipose–liver signaling axis contributing to fibrotic progression.
OrsoBio’s LXR inverse agonist shows promise for hard-to-treat triglyceride disorders
February 23, 2026 / LXR Inverse Agonist TLC-2716 / Severe Hypertriglyceridemia Treatment / Remnant Cholesterol Reduction / MASH Drug Development / Mitochondrial Protonophore Therapy
OrsoBio’s LXR inverse agonist TLC-2716 reduced triglycerides, remnant cholesterol, and liver fat in Phase 2a, targeting severe hypertriglyceridemia and MASH without LXR agonist–associated lipid increases. The company is also advancing mitochondrial protonophores to enhance energy expenditure in obesity.
Light-Intensity Physical Activity Shows Mortality Benefit Across Cardiovascular-Kidney-Metabolic Syndrome Stages
February 20, 2026 / Light-Intensity Physical Activity / CKM Syndrome Mortality Risk / Cardiovascular Kidney Metabolic Health / Sedentary Behavior Reduction / NHANES Cohort Study
In US adults with stage ≥2 CKM syndrome, higher light-intensity physical activity was associated with 14–20% lower all-cause mortality per additional hour daily, with greatest absolute benefit in advanced stages, supporting sedentary time replacement in high-risk populations.
New study reveals who is most at risk for CKMS in the U.S.
February 23, 2026 / Cardiovascular Kidney Metabolic Syndrome / CKMS Health Disparities / Black American Cardiometabolic Risk / Rural Health Inequities / U.S. CKMS Prevalence Data
National data reveal high U.S. prevalence of cardiovascular-kidney-metabolic syndrome, with advanced CKMS disproportionately affecting Black Americans, women, rural residents, and lower-income groups, underscoring significant sociodemographic disparities and the need for targeted prevention across the lifespan.
Metabolic disease, misaligned incentives, and what I learnt at WHX Dubai
February 18, 2025 / Metabolic Disease in Gulf Region / Non-Communicable Disease Prevention / Cardiovascular Kidney Metabolic Burden / Predictive Health Intelligence / Healthcare Incentive Misalignment
Metabolic disease prevalence in Gulf countries exceeds Western rates, driving cardiovascular, renal, hepatic, and neurodegenerative burden. Despite NCDs causing 74% of global deaths, <2% of spending targets prevention, highlighting systemic incentive misalignment and urgent need for predictive, upstream intervention models.
Zandra Healthcare launches Metabolic Health Centre with AI-based diagnostics
February 23, 2026 / AI-Based Metabolic Care / Predictive Diabetes Management / Diabetic Foot AI Screening / GLP-1 Integrated Treatment / Metabolic Syndrome Diagnostics
Zandra Healthcare’s Metabolic Health Centre integrates AI-driven diagnostics, rapid point-of-care cardiometabolic testing, gait-based diabetic foot prevention, sleep and pulmonary assessment, and body composition profiling, advancing predictive, multi-organ management of obesity, diabetes, and metabolic syndrome complications.
Combining gene and biomarker screening for newborn health
February 23, 2026 / Newborn Genetic Screening / Inherited Metabolic Disorders / Next-Generation Sequencing in Neonates / Dried Blood Spot Testing / Precision Public Health Screening
A national consensus recommends integrating dried blood spot biomarkers with high-coverage next-generation sequencing to improve early detection of 67 inherited metabolic disorders, enhancing diagnostic accuracy, reducing false results, and enabling timely intervention while maintaining ethical and cost-effectiveness safeguards.
Biomea Fusion advances metabolic disease science with visionary approach
February 18, 2026 / Biomea Fusion Metabolic Pipeline / Metabolic Disease Therapeutics / Disease-Modifying Treatments / Cardiometabolic Drug Development / Innovative Endocrine Therapies
Biomea Fusion highlights its long-term, disciplined strategy to advance innovative scientific approaches targeting metabolic diseases, reinforcing its commitment to developing disease-modifying therapies aimed at improving outcomes in chronic cardiometabolic conditions.
Targeting immunometabolic pathways with AZD1656 alleviates inflammation and metabolic dysfunction in type 2 diabetic cardiomyopathy
February 23, 2025 / AZD1656 Glucokinase Activator / Diabetic Cardiomyopathy Treatment / Immunometabolic Pathways / Regulatory T Cells in Heart Disease / Type 2 Diabetes Cardiac Dysfunction
In a type 2 diabetic cardiomyopathy mouse model, the glucokinase activator AZD1656 improved cardiac function, reduced infarct size, restored mitochondrial metabolism, and attenuated fibrosis by promoting regulatory T-cell infiltration, highlighting immunometabolic modulation as a therapeutic strategy.